AlphAIAlphAI — Financial news for AI agents
tradingview.com$LQDA

Liquidia 3Q 2026: Revenue $225.3M, EPS ($2.64) — 10-Q Summary

Liquidia reported 3Q 2026 revenue of $225.3M, up 314.6% YoY, driven by YUTREPIA sales. Net loss widened to $236.33M, or $2.64 per share, due to a $389.7M litigation settlement charge and higher R&D expenses. The company also advanced its L606 program and initiated a new YUTREPIA study.

Original reporting
tradingview.com
Published Nov 10, 2026, 11:51 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 11:59 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Liquidia 3Q 2026: Revenue $225.3M, EPS ($2.64) — 10-Q Summary — source image
Source · tradingview.com
Decision brief

The 30-second read

$LQDABearishMed
01

Why it matters

The disclosed settlement charge creates immediate downside risk, but the revenue growth and pipeline activity may offer longer‑term catalysts.

02

Market read

First‑time disclosure of a large settlement for a small‑cap biotech, likely prompting a sell‑off in LQDA and influencing sector risk sentiment.

03

What to watch

Potential upside from upcoming YUTREPIA clinical data and L606 pipeline progress.

Relevance 7/10Novelty 8/10Timing: post‑market filing

Background

Liquidia Corp (LQDA) filed its Form 10‑Q for the quarter ending September 2026, highlighting a revenue surge driven by YUTREPIA sales and a substantial litigation settlement.

Company-level read

Ticker impact

$LQDABearishHigh confidence
Context

Liquidia reported Q3 2026 results with revenue $225.3M and a $389.7M litigation settlement charge, a first‑time disclosure from its 10‑Q filing.

Expected impact

downward pressure as the market prices in the large settlement expense

Evidence & confidence

A $389.7M charge for a small‑cap biotech is material and newly disclosed, creating immediate downside risk.

Market effects

Sector

Biotech sector may see heightened scrutiny on litigation exposure.

Regional

U.S. biotech investors may adjust risk models for similar companies.

Global

Limited to investors tracking U.S. small‑cap biotech stocks.

Counterpoint

What could challenge this read

If the settlement resolves a major liability, future earnings could improve once the charge is absorbed.

Key entities

  • company
    Liquidia Corp

    Biotech firm reporting Q3 2026 results and settlement.

  • counterparty
    UTC

    Recipient of the $330.4M settlement payment.

Read at source← All news

StoryLiquidia posts strong Q3 sales and adjusted EBITDA growth, but GAAP loss driven by $389.7M settlement charge

Also covered by

5 outlets

Related articles

$LQDAMedAI 8/10

Why is Liquidia stock gaining today?

Liquidia Corporation (LQDA) shares rose 1.4% in pre-market trading after reporting Q3 2026 results. Revenue of $225.3M beat estimates, driven by $222.7M in YUTREPIA sales, up 31% from the prior quarter. A $389.7M litigation charge resulted in a GAAP net loss of $2.64 per share, but operational metrics showed growth, including record patient shipments and an expanding prescriber base. The company's cash position increased to $396.1M.

investing.com
$LQDAMed

Liquidia Reports Strong Third-Quarter YUTREPIA Sales Growth

Liquidia (LQDA) reported Q3 2026 net sales of $222.7M for YUTREPIA, up 31% from Q2, with October patient shipments at a record high. The company settled litigation with United Therapeutics, incurring a $389.7M charge and a Q3 net loss of $236.3M. Non-GAAP adjusted EBITDA was $140.5M, up for the fifth consecutive quarter. Cash reserves were $396.1M at Q3's end. The FDA granted Fast Track designation to YUTREPIA for a new indication, and the company initiated two new studies.

tipranks.com
$LQDAHighAI 8/10

Liquidia Corporation Reports Third Quarter 2026 Financial Results

Liquidia Corp (LQDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Liquidia Corporation Reports Third Quarter 2026 Financial Results · YUTREPIA® (treprostinil) inhalation powder net product sales of $222.7 million in the third quarter of 2026, up 31% from the second quarter of 2026 · October 2026 total patient shipments reached thei

SEC EDGAR 8-K